STOCK TITAN

Surrozen (SRZN) Stock Price, News & Analysis

SRZN NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
77 252 sessions, November 14, 2025 to November 16, 2026
Largest daily move
+108.4% close of September 24, 2026
1-year change
+149% closing prices, November 14, 2025 to November 16, 2026
1-month change
+37.9% closing prices, October 16, 2026 to November 16, 2026

Company Description

Surrozen, Inc. (Nasdaq: SRZN) is a biotechnology company developing targeted therapeutics that selectively modulate the Wnt pathway, a signaling system associated with tissue repair and regeneration. According to company disclosures, Surrozen focuses its research and development on severe eye diseases in ophthalmology, using proprietary antibody-based technologies to influence Wnt signaling in a tissue-specific manner.

The company describes its approach as pioneering a new class of Wnt-based therapeutics designed to repair and restore tissue function. Surrozen develops multifunctional biologics and tissue-specific antibodies that selectively activate Wnt signaling, alone or in combination with other disease pathways. Its stated goal is to address serious ophthalmic diseases with high unmet medical need by harnessing the body’s biological repair mechanisms.

Ophthalmology focus and Wnt pathway modulation

Surrozen reports that it remains focused on an ophthalmology pipeline built on Wnt biology expertise and antibody technologies. The company’s programs are directed at retinal vascular diseases, where abnormal blood vessel growth and leakage can impair vision. By targeting the Wnt pathway and other molecular pathways, Surrozen aims to promote normal retinal vessel regrowth while suppressing pathological vessel growth in preclinical models.

The company’s disclosures describe Wnt-based therapeutics as tissue-specific antibodies and multifunctional biologics that selectively activate Wnt signaling. These molecules are designed to modulate key receptors, including Frizzled (Fzd) and low-density lipoprotein receptor-related proteins (LRP5/6), which are involved in Wnt pathway signaling. Surrozen states that its technologies are intended to tune potency and selectivity through antibody valency and binding properties.

Key product candidates in retinal diseases

Surrozen highlights several preclinical product candidates within its ophthalmology portfolio. SZN-8141 is described as a candidate for retinal diseases that combines Frizzled 4 (Fzd4) agonism and vascular endothelial growth factor (VEGF) antagonism. Company materials state that this dual mechanism has the potential to provide benefits over treatment with single agents for conditions such as diabetic macular edema (DME) and neovascular age-related macular degeneration (wet AMD). In preclinical models of retinal vascular diseases, SZN-8141 has been reported to stimulate Wnt signaling, induce normal retinal vessel regrowth, and suppress pathological vessel growth.

SZN-8143 is another retinal disease candidate that, according to Surrozen, combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism. The company indicates that this combination may offer benefits over single agents for DME, wet AMD, and uveitic macular edema (UME). In preclinical models of retinal vascular diseases, Surrozen reports that SZN-8143 stimulated Wnt signaling, induced normal retinal vessel regrowth, and suppressed pathological vessel growth.

SZN-413 is described as a bi-specific antibody targeting Fzd4-mediated Wnt signaling and designed using Surrozen’s SWAP™ technology. Surrozen reports that SZN-413 is being developed for retinal vascular-associated diseases, including through a strategic partnership with Boehringer Ingelheim. In preclinical models of retinopathy, SZN-413 has been reported to potently stimulate Wnt signaling in the eye, induce normal retinal vessel regrowth, suppress pathological vessel growth, and reduce vascular leakage. Company statements suggest that this approach could potentially allow for regeneration of healthy eye tissue.

Proprietary platforms and intellectual property

Surrozen’s disclosures emphasize a proprietary antibody-engineering platform and technologies for creating Wnt surrogate molecules. The company describes its Wnt surrogates as tetravalent antibodies that bring together antibody-binding domains targeting Frizzled receptors and LRP5/6. It reports that multivalent binding to Fzd and LRP is a requirement for maximal signaling through selective surrogate Wnt molecules, and that potency and effects can be tuned through valency and binder properties.

The company has announced the issuance of U.S. Patent No. 12,297,278 related to its SWAP™ technology, which covers tetravalent, multi-specific Wnt surrogates comprised of two Fzd binding regions and two LRP5/6 binding regions. Surrozen states that this patent is part of an expanding intellectual property portfolio directed to generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and incorporating discoveries related to requirements for efficient and selective Wnt pathway signaling.

Surrozen has disclosed a collaboration agreement with TCGFB, Inc. under which the company provided antibody discovery services. Under that agreement, TCGFB owned all TGF-β product-related intellectual property, and Surrozen was entitled to research service payments and a warrant to purchase TCGFB common stock, subject to vesting conditions. The collaboration was characterized as a related party transaction because entities affiliated with The Column Group hold more than 5% of Surrozen’s common stock and a member of Surrozen’s board serves as Managing Partner of The Column Group. The agreement was later terminated by TCGFB for convenience without termination penalties, as reported in an 8-K filing.

Surrozen also reports a strategic partnership and agreement with Boehringer Ingelheim for SZN-413 and other Fzd4-specific Wnt-modulating molecules. Under the terms described by the company, Boehringer Ingelheim received an exclusive worldwide license to develop SZN-413 and related molecules for all purposes, including treatment of retinal diseases, in exchange for an upfront payment and the potential for success-based development, regulatory, and commercial milestone payments, plus royalties on sales.

Clinical development plans and stage

Company communications describe Surrozen as a clinical-stage biotechnology company in some contexts and as a biotechnology company developing tissue-specific antibodies with a current focus on ophthalmology in others. Surrozen reports that it continues to progress its lead candidates SZN-8141 and SZN-8143 in retinal diseases and has stated an intention to submit an Investigational New Drug (IND) application for SZN-8141. The company also notes that Fzd4 monotherapy has demonstrated proof of concept in DME and retinal disease in clinical trials, and that current standard of care in several retinal vascular conditions involves intravitreal administration of anti-VEGF monotherapies.

Surrozen’s disclosures emphasize discovery, research and development activities, including preclinical studies and scientific presentations at ophthalmology-focused conferences and meetings. The company has highlighted presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Clinical Trials at the Summit, and other ophthalmology innovation events, where it has shared data on next-generation Wnt therapeutics in retinal diseases.

Management, governance and exchange listing

Surrozen’s securities trade on Nasdaq under the symbol SRZN. The company has reported appointments and changes in key leadership roles through SEC filings and press releases, including the appointment of a Chief Financial Officer and the continued role of a Chief Operating Officer. It has also reported inducement stock option grants under its equity inducement plan in accordance with Nasdaq Listing Rule 5635(c)(4), reflecting the use of equity-based compensation to attract new employees.

Through its public filings, Surrozen also describes standard governance practices such as indemnification agreements for executive officers and disclosure of related party transactions. These filings provide additional context on compensation arrangements, severance benefits, and collaboration structures.

Risk disclosures and forward-looking statements

Surrozen’s press releases and SEC filings contain forward-looking statements regarding its discovery, research and development activities, development plans and timelines for product candidates, potential clinical applications in serious eye diseases, and expectations related to collaborations and partnerships. The company notes that these statements are based on assumptions and current expectations and are subject to risks and uncertainties, including factors discussed under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. Surrozen cautions that actual results may differ materially from those implied by forward-looking statements and that it undertakes no obligation to update such statements except as required by law.

Stock Performance

$32.32
+2.25%
+0.71
Last updated: November 16, 2026 at 16:00
+149%
Performance 1 year
$616.1M

Surrozen (SRZN) closed at $32.32 on November 16, 2026. Over the past 12 months, the price has gained 149.0%.

See what a $1,000 investment in SRZN would be worth today

Average down calculator for SRZN

SRZN Metrics & Rankings

Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Financial Highlights

Surrozen generated $3.5M in revenue in FY2025, operating income reached -$42.1M, and net income was -$242.0M. Diluted earnings per share stood at -$32.37. The company generated -$30.2M in operating cash flow. The current ratio was 9.22, measuring current assets divided by current liabilities.

$3.5M
Revenue (FY2025)
-$242.0M
Net Income (FY2025)
-$30.2M
Operating Cash Flow

Upcoming Events

DEC
31
December 31, 2026 Clinical

DUET trial start

DUET Phase 1b/2a trial to start by 2026-12-31 following IND filing with FDA; tests SZN-8141 in DME patients.
DEC
31
December 31, 2026 Clinical

DUET Phase 1b/2a initiation

Surrozen intends to initiate the DUET Phase 1b/2a trial by 2026-12-31; trial start expected across clinical sites with updates.
FEB
17
February 17, 2027 Corporate

25% option vesting

25% of 3,070 non-statutory options vest; strike $24.53; minor dilution potential
FEB
17
February 17, 2027 - February 17, 2030 Corporate

Monthly vesting period

Remaining 75% vests monthly over 36 months following the one-year cliff (grant tied to 2026-02-17 price)
APR
24
April 24, 2027 Corporate

25% vesting

25% (505 shares) of 2,020 stock options vest on the one-year anniversary under the 2025 Inducement Plan; exercise price $28.14.
APR
24
April 24, 2027 - April 24, 2030 Corporate

Monthly ratable vesting

Remaining 1,515 options vest ratably monthly over 36 months under the 2025 Inducement Plan; exercise price $28.14.
H2
2027
H2 2027 Clinical

DUET initial data

Surrozen expects initial DUET Phase 1b/2a data in the second half of 2027 (2027-07-01 to 2027-12-31); early efficacy/safety readouts.
H2
2027
H2 2027 Clinical

Phase 1b topline data

Topline readout for SZN-8141 Phase 1b in DUET (diabetic macular edema); expected H2 2027; potential investor webcast.
YEAR
2028
2028 Clinical

Phase 2a data

Phase 2a data readout for SZN-8141 in DUET (diabetic macular edema); expected in 2028; enrollment expansion to ~150 patients.
YEAR
2029
2029 Clinical

SZN-8141 DUET completion

Surrozen expects completion of the SZN-8141 DUET Phase 1b/2a study by 2029; milestone tied to funding and development progress.
YEAR
2029
2029 Clinical

SZN-8143 Phase 1b start

Surrozen plans initial Phase 1b clinical development of SZN-8143 expected during 2029; funding noted to support this work.

Surrozen has 11 upcoming scheduled events. The next event, "DUET trial start", is scheduled for December 31, 2026 (in 45 days). Investors can track these dates to stay informed about potential catalysts that may affect the SRZN stock price.

Short Interest History

Last 12 Months

Short interest in Surrozen (SRZN) currently stands at 3.2 million shares, up 3.3% from the previous reporting period, representing 17.8% of the float. Since November 2025, short interest has increased by 2058.4%.

Days to Cover History

Last 12 Months

Days to cover for Surrozen (SRZN) currently stands at 8.5 days, up 78.4% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 305.2%. Across the settlements charted above, it has ranged from 1.2 to 12.7 days.

SRZN Company Profile & Sector Positioning

Surrozen (SRZN) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing SRZN often look at related companies in the same sector, including Aclaris Therapeutics, Inc. (ACRS), Design Therapeutics, Inc. (DSGN), Immix Biopharma, Inc. (IMMX), Climb Bio, Inc. (CLYM), and Sana Biotechnology, Inc. (SANA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SRZN's relative position within its industry.

Frequently Asked Questions

The current stock price of Surrozen (SRZN) is $32.32 as of November 16, 2026.

The market cap of Surrozen (SRZN) is approximately $616.1M. Learn more about what market capitalization means .

The FY2025 revenue of Surrozen (SRZN) is $3.5M, from its most recent completed fiscal year.

The FY2025 net income of Surrozen (SRZN) is -$242.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Surrozen (SRZN) is -$32.37 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Surrozen (SRZN) is -$30.2M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Surrozen (SRZN), current assets divided by current liabilities, was 9.22 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Surrozen (SRZN) is -$42.1M for FY2025, its most recent completed fiscal year. Learn about operating income.

Surrozen, Inc. is a biotechnology company that develops targeted therapeutics designed to selectively modulate the Wnt pathway. The company focuses on severe eye diseases in ophthalmology and works on tissue-specific antibodies and multifunctional biologics intended to repair and restore tissue function.

Surrozen reports a primary focus on ophthalmology, particularly retinal vascular diseases such as diabetic macular edema and neovascular age-related macular degeneration. Its product candidates are designed to modulate Wnt signaling and other pathways in the eye to promote normal retinal vessel regrowth and suppress pathological vessel growth in preclinical models.

According to company disclosures, Surrozen develops tissue-specific antibodies and multifunctional biologics that selectively activate Wnt signaling. Its Wnt surrogate molecules are tetravalent antibodies that bind Frizzled and LRP5/6 receptors, with multivalent binding described as important for maximal Wnt signaling in its selective surrogate Wnt molecules.

Surrozen highlights SZN-8141, SZN-8143, and SZN-413 in its ophthalmology portfolio. SZN-8141 combines Fzd4 agonism and VEGF antagonism, SZN-8143 combines Fzd4 agonism, VEGF antagonism, and IL-6 antagonism, and SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed with the company’s SWAP™ technology. All three have shown effects on retinal vessel regrowth and pathological vessel growth in preclinical models, according to the company.

Surrozen describes SWAP™ technology as an antibody-engineering platform used to create multi-specific Wnt surrogate molecules. A U.S. patent related to this technology covers tetravalent, multi-specific Wnt surrogates with two Frizzled binding regions and two LRP5/6 binding regions, each comprising antibody or antigen-binding fragments fused via linker moieties.

Yes. Surrozen has disclosed a strategic partnership with Boehringer Ingelheim, which holds an exclusive worldwide license to develop SZN-413 and other Fzd4-specific Wnt-modulating molecules for all purposes, including treatment of retinal diseases. Surrozen has also reported a collaboration agreement with TCGFB, Inc. for antibody discovery services, which TCGFB later elected to terminate for convenience without penalties.

Surrozen’s common stock trades on Nasdaq under the ticker symbol SRZN, as stated in its press releases and SEC filings.

Company communications describe Surrozen as a biotechnology company with discovery, research and development activities focused on Wnt-based therapeutics. It reports that SZN-8141 and SZN-8143 are progressing in retinal diseases and that it intends to submit an Investigational New Drug (IND) application for SZN-8141, indicating that these programs are in preclinical development.

Surrozen states that SZN-8141 and SZN-8143 may provide benefits over single-agent therapies for retinal vascular diseases by combining Fzd4 agonism with VEGF and, for SZN-8143, IL-6 antagonism. In preclinical models, these candidates have been reported to stimulate Wnt signaling, induce normal retinal vessel regrowth, and suppress pathological vessel growth.

Surrozen indicates that detailed risk information is provided in the “Risk Factors” sections of its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. The company references these filings in its forward-looking statement disclaimers.